NanoString Technologies Announces Adoption of Prosigna Breast Cancer Assay by Leading US Clinical Laboratories and Cancer Centers

NanoString Technologies NSTG today announced nationwide availability of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of 2014. Premier national diagnostic laboratories ARUP Laboratories, Laboratory Corporation of America® Holdings (LabCorp®) (LH), and Quest Diagnostics (DGX) have chosen to add the Prosigna Assay to their comprehensive suites of breast cancer diagnostic tests, providing patients treated throughout the U.S. with timely access to a genomic assay that assesses a tumor's underlying biology and risk of distant recurrence. NanoString Technologies also announced that laboratories at the University of Alabama at Birmingham Comprehensive Cancer Center and University of North Carolina Lineberger Comprehensive Cancer Center will be among the initial wave of facilities to offer the Prosigna Assay in 2014.